Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
228 Results for "
LDL
" in MedChemExpress (MCE) Product Catalog:
Products (228)
228 Results for "LDL" in MCE Product Catalog:
Cat. No.: HY-158827
CAS No.: 2604215-74-7
Target:
Research Areas:
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
Cat. No.: HY-W791754
CAS No.: 827610-11-7
Target:
Research Areas:
Paeonolsilate (sodium) can inhibit ox-LDL-induced macrophage foam cell formation and inflammation in atherosclerosis. Paeonolsilate (sodium) inhibits NF-κB activation and oxidative stress response induced by ox-LDL. Paeonolsilate (sodium) can be studied in anti-atherosclerosis research .
Cat. No.: HY-125554
CAS No.: 439904-34-4
Target:
Research Areas:
KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL) .
Target:
Research Areas:
Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels .
Cat. No.: HY-161435
Target:
Research Areas:
PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .
Cat. No.: HY-128334
CAS No.: 2365416-53-9
Target:
Research Areas:
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .
Cat. No.: HY-19251
CAS No.: 107376-72-7
Target:
Research Areas:
CL-283796 is a potent and orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. CL-283796 reduces low-density lipoprotein (LDL) cholesterol without affecting cholesterol absorption in African green monkeys. CL-283796 can be used for hypercholesterolemia research .
Cat. No.: HY-119265
CAS No.: 615264-62-5
Target:
Research Areas:
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .
Target:
Research Areas:
LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC50 = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC50s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research .
Cat. No.: HY-U00054
CAS No.: 180908-67-2
Target:
Research Areas:
LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.
Cat. No.: HY-123016A
CAS No.: 33783-76-5
Target:
Research Areas:
(±)9-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL.2 Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 9-HODE cholesteryl ester.
Cat. No.: HY-W747575
CAS No.: 167354-91-8
Target:
Research Areas:
(±)13-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 13-HODE cholesteryl ester.
Cat. No.: HY-165512
CAS No.: 150443-71-3
Target:
Research Areas:
Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).
Cat. No.: HY-147279
CAS No.: 2643306-81-2
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .
Cat. No.: HY-N0339S
CAS No.: 84759-06-8
Cat. No.: HY-B0388S1
Synonyms: DH-581-d6
Cat. No.: HY-P3731
CAS No.: 237392-85-7
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
Cat. No.: HY-B0388S
CAS No.: 1173019-29-8
Cat. No.: HY-118518
CAS No.: 85247-77-4
Target:
Research Areas:
Ronipamil is a calcium ion antagonist. Ronipamil increases the specific binding and internalization of human 125I-LDL in human skin fibroblasts (HSF) and the human hepatoma cell line Hep G2 .
Cat. No.: HY-155006
Target:
Research Areas:
PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
